ALZAMEND NEURO INC (ALZN) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:ALZN • US02262M6057

2.09 USD
-0.08 (-3.69%)
At close: Feb 3, 2026
2.2343 USD
+0.14 (+6.9%)
After Hours: 2/3/2026, 8:00:00 PM
Fundamental Rating

2

Overall ALZN gets a fundamental rating of 2 out of 10. We evaluated ALZN against 524 industry peers in the Biotechnology industry. ALZN scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. ALZN has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • ALZN had negative earnings in the past year.
  • ALZN had a negative operating cash flow in the past year.
  • ALZN had negative earnings in each of the past 5 years.
  • In the past 5 years ALZN always reported negative operating cash flow.
ALZN Yearly Net Income VS EBIT VS OCF VS FCFALZN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 2025 -5M -10M

1.2 Ratios

  • ALZN's Return On Assets of -127.12% is on the low side compared to the rest of the industry. ALZN is outperformed by 79.77% of its industry peers.
  • ALZN's Return On Equity of -147.97% is on the low side compared to the rest of the industry. ALZN is outperformed by 63.74% of its industry peers.
Industry RankSector Rank
ROA -127.12%
ROE -147.97%
ROIC N/A
ROA(3y)-645.75%
ROA(5y)-439.18%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ALZN Yearly ROA, ROE, ROICALZN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 2025 0 -500 -1K -1.5K

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for ALZN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ALZN Yearly Profit, Operating, Gross MarginsALZN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 2025

More info and screens

6

2. Health

2.1 Basic Checks

  • The number of shares outstanding for ALZN has been increased compared to 1 year ago.
  • ALZN has more shares outstanding than it did 5 years ago.
  • ALZN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ALZN Yearly Shares OutstandingALZN Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 2025 200K 400K 600K
ALZN Yearly Total Debt VS Total AssetsALZN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 2025 5M 10M

2.2 Solvency

  • Based on the Altman-Z score of -13.34, we must say that ALZN is in the distress zone and has some risk of bankruptcy.
  • The Altman-Z score of ALZN (-13.34) is worse than 77.29% of its industry peers.
  • ALZN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -13.34
ROIC/WACCN/A
WACCN/A
ALZN Yearly LT Debt VS Equity VS FCFALZN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 2025 0 5M -5M 10M

2.3 Liquidity

  • A Current Ratio of 6.58 indicates that ALZN has no problem at all paying its short term obligations.
  • The Current ratio of ALZN (6.58) is better than 66.98% of its industry peers.
  • ALZN has a Quick Ratio of 6.58. This indicates that ALZN is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 6.58, ALZN is in the better half of the industry, outperforming 67.75% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 6.58
Quick Ratio 6.58
ALZN Yearly Current Assets VS Current LiabilitesALZN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 2025 5M 10M

More info and screens

1

3. Growth

3.1 Past

  • ALZN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 90.48%, which is quite impressive.
EPS 1Y (TTM)90.48%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%91.23%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • ALZN is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 19.94% yearly.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y67.29%
EPS Next 2Y33.94%
EPS Next 3Y21.42%
EPS Next 5Y19.94%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ALZN Yearly Revenue VS EstimatesALZN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2029 2030 2031 2032 2033 100M 200M 300M 400M
ALZN Yearly EPS VS EstimatesALZN Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 -50 -100 -150 -200

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for ALZN. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ALZN. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ALZN Price Earnings VS Forward Price EarningsALZN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ALZN Per share dataALZN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4

4.3 Compensation for Growth

  • A more expensive valuation may be justified as ALZN's earnings are expected to grow with 21.42% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y33.94%
EPS Next 3Y21.42%

More info and screens

0

5. Dividend

5.1 Amount

  • No dividends for ALZN!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

ALZAMEND NEURO INC

NASDAQ:ALZN (2/3/2026, 8:00:00 PM)

After market: 2.2343 +0.14 (+6.9%)

2.09

-0.08 (-3.69%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)12-09
Earnings (Next)03-09
Inst Owners3.88%
Inst Owner Change15.24%
Ins Owners2.17%
Ins Owner Change-1.08%
Market Cap7.94M
Revenue(TTM)N/A
Net Income(TTM)-6.47M
Analysts80
Price Target28.56 (1266.51%)
Short Float %4.78%
Short Ratio2.07
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)1.54%
Min EPS beat(2)-81.87%
Max EPS beat(2)84.96%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-33.33%
PT rev (3m)-33.33%
EPS NQ rev (1m)6.55%
EPS NQ rev (3m)6.55%
EPS NY rev (1m)9.8%
EPS NY rev (3m)9.8%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.82
P/tB 1.82
EV/EBITDA N/A
EPS(TTM)-5.71
EYN/A
EPS(NY)-3.04
Fwd EYN/A
FCF(TTM)-1.54
FCFYN/A
OCF(TTM)-1.49
OCFYN/A
SpS0
BVpS1.15
TBVpS1.15
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -127.12%
ROE -147.97%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-645.75%
ROA(5y)-439.18%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 260.22%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.58
Quick Ratio 6.58
Altman-Z -13.34
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)294.02%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)90.48%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%91.23%
EPS Next Y67.29%
EPS Next 2Y33.94%
EPS Next 3Y21.42%
EPS Next 5Y19.94%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-0.76%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-50.07%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y34.92%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y36.21%
OCF growth 3YN/A
OCF growth 5YN/A

ALZAMEND NEURO INC / ALZN FAQ

What is the ChartMill fundamental rating of ALZAMEND NEURO INC (ALZN) stock?

ChartMill assigns a fundamental rating of 2 / 10 to ALZN.


Can you provide the valuation status for ALZAMEND NEURO INC?

ChartMill assigns a valuation rating of 1 / 10 to ALZAMEND NEURO INC (ALZN). This can be considered as Overvalued.


How profitable is ALZAMEND NEURO INC (ALZN) stock?

ALZAMEND NEURO INC (ALZN) has a profitability rating of 0 / 10.


What is the expected EPS growth for ALZAMEND NEURO INC (ALZN) stock?

The Earnings per Share (EPS) of ALZAMEND NEURO INC (ALZN) is expected to grow by 67.29% in the next year.